Medical Market Report

Global AT1 Receptor Antagonists Market By Type (Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, and Olmesartan), By Application (Hypertension, Cardiovascular Diseases, and Kidney Diseases), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 135886
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global AT1 Receptor Antagonists Market is estimated to be valued US$ XX.X million in 2019. The report on AT1 Receptor Antagonists Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global at1 receptor antagonists market is segmented on the basis of Type, Application, and geography.

    In 2019, the North America market is valued US$ XX.X million and the market share is estimated X.X%, and it is expected to be US$ XX.X million and X.X% in 2029, with a CAGR X.X% from 2020 to 2029.

    AT1 Receptor Antagonists Market Scope:

    By type, the market is segmented into Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, and Olmesartan. By Application, the market is divided into Hypertension, Cardiovascular Diseases, and Kidney Diseases.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb, Bayer, GSK, and Teva Pharmaceutical.

    Key Market Segments

    Type

    Valsartan

    Telmisartan

    Losartan

    Irbesartan

    Azilsartan

    Olmesartan

    Application

    Hypertension

    Cardiovascular Diseases

    Kidney Diseases

    Key Market Players included in the report:

    Pfizer

    Novartis

    Merck

    Astra Zeneca

    Jhonson and Johnson

    Eli Lilly and Company

    Sanofi SA

    Bristol-Myers Squibb

    Bayer

    GSK

    Teva Pharmaceutical

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and AT1 Receptor Antagonists Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of AT1 Receptor Antagonists Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers AT1 Receptor Antagonists Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global AT1 Receptor Antagonists Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the AT1 Receptor Antagonists Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the AT1 Receptor Antagonists Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of AT1 Receptor Antagonists sub-markets, depending on key regions (various vital states).
    To analyze AT1 Receptor Antagonists Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the AT1 Receptor Antagonists Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide AT1 Receptor Antagonists Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. AT1 Receptor Antagonists Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players3. Global AT1 Receptor Antagonists Market Overview
    

    3.1. AT1 Receptor Antagonists Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges  3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy4. Global AT1 Receptor Antagonists Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global AT1 Receptor Antagonists Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Valsartan
    

      4.4. Telmisartan
    

      4.5. Losartan
    

      4.6. Irbesartan
    

      4.7. Azilsartan
    

      4.8. Olmesartan5. Global AT1 Receptor Antagonists Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global AT1 Receptor Antagonists Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Hypertension
    

      5.4. Cardiovascular Diseases
    

      5.5. Kidney Diseases6. Global AT1 Receptor Antagonists Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America AT1 Receptor Antagonists Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe AT1 Receptor Antagonists Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific AT1 Receptor Antagonists Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America AT1 Receptor Antagonists Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa AT1 Receptor Antagonists Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    
7. Global AT1 Receptor Antagonists Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Pfizer
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments  7.4. Novartis
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments  7.5. Merck
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments  7.6. Astra Zeneca
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments  7.7. Jhonson and Johnson
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments  7.8. Eli Lilly and Company
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments  7.9. Sanofi SA
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments  7.10. Bristol-Myers Squibb
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments  7.11. Bayer
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments  7.12. GSK
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments  7.13. Teva Pharmaceutical
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.